AcouSort (ACOU) Q1 2025 earnings summary

Executive summary

• Achieved continued progress in flow cytometry and cell therapy, with new and extended collaborations in Q1 2025, including Bio-ReCell and a UK-based sepsis treatment company.

• Rights issue completed in May 2025, raising MSEK 24.9 (73% subscribed), providing financial stability for ongoing business development.

• Participation in major industry events and increased marketing efforts led to a higher influx of potential OEM projects.

Financial highlights

• Q1 2025 net sales: TSEK 1,595 (Q1 2024: 1,357); total income: MSEK 2.6 (3.0); royalty income: MSEK 1.3 (0.84).

• Operating result: TSEK -3,333 (Q1 2024: -4,300); result before tax: TSEK -4,022 (-3,729); EPS: SEK -0.27 (-0.25).

• Cash and cash equivalents at period end: TSEK 3,448 (20,377); equity ratio: 41% (71%).

• Parent company Q1 2025 net sales: TSEK 1,569 (1,357); result before tax: TSEK -3,915 (-3,090); equity ratio: 54% (76%).

Outlook and guidance

• Focus remains on strengthening positions in diagnostics, cell therapy, flow cytometry, and quality control through expanded partnerships.

• Rights issue proceeds, royalties, public funding, and projected revenues expected to fund activities into 2027.

• Ambition to convert collaborations into long-term OEM partnerships and drive commercialization.